🇺🇸 FDA

Intelligence · Patent portfolio

Prime Medicine Patents

Full USPTO pharma patent portfolio for Prime Medicine — grant dates, expiration, and drug cross-links.

Patents
127
Expiring ≤24m
1

Quick answer

Prime Medicine has 127 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 1 expire within 24 months — use filters for patent-cliff planning.

Page 2 of 3

  1. US 10975153

    Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10945964

    Microencapsulated chitosan, methods of making and methods for the use thereof

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10946080

    Compositions and methods for combination therapy with dengue virus and dendritic cells

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10822421

    Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10799559

    NOPE for treatment of pathological muscle loss and weakness

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10765705

    Visco-supplement compositions, and methods of use thereof

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10765727

    Compositions and methods for producing dendritic cells

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10730949

    Method of treating PVNS with anti-CSF1R antibodies

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10675304

    Combination immunotherapies for treatment of cancer

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10618967

    Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

    Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10576107

    Methods of treating joint diseases, disorders, and conditions with tissue inhibitors of matrix metalloproteinases

    Expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10562970

    Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10537611

    Methods of treating lung cancer

    Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10517902

    Expandable amnion membrane for treating non-healing wounds

    Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10383927

    Variable epitope library compositions and methods of therapeutic and prophylactic use

    Expires Mon Aug 15 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10357553

    Compositions and methods for combination therapy with dengue virus and dendritic cells

    Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10273281

    CD80 extracellular domain polypeptides and their use in cancer treatment

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10221244

    Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10221243

    Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10195612

    Small particle compositions and associated methods

    Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10172937

    Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodies

    Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10159727

    Compositions and methods for combination therapy with dengue virus and dendritic cells

    Expires Mon Dec 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10130676

    Therapeutic peptides for cerebrovascular diseases

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10064923

    Therapeutic cancer vaccines derived from a novel dendritic cell line

    Expires Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10040858

    Anti-CSF1R antibodies for treating PVNS

    Expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10023627

    Vascular endothelial growth factor fusion protein

    Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10016484

    Methods of treating lung cancer

    Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9957327

    Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9849167

    Compositions and methods for combination therapy with dengue virus and dendritic cells

    Expires Mon Dec 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9775881

    Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD

    Expires Mon Sep 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9765147

    Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9730989

    Compositions and methods for combination therapy with dengue virus and dendritic cells

    Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9713637

    Bacillus anthracis HtrA-defective-derived vaccines

    Expires Mon Jul 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9695243

    Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Expires Mon Jun 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9657267

    Ex host maturation of germline stem cells

    Expires Mon May 18 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9475871

    Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins

    Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9200075

    Nucleic acids encoding antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9192683

    Methods of treating disease with FGFR1 fusion proteins

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9175065

    FGFR extracellular domain acidic region muteins

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9173957

    FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9169313

    Method of treatment of cancers characterized by ligand-dependent activating mutations in FGFR2 with FGFR1 ECD proteins

    Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8951972

    FGFR1 extracellular domain combination therapies for lung cancer

    Expires Mon Feb 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8920800

    Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins

    Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8901277

    Interferon alpha mutant and its polyethylene glycol derivative

    Expires Mon Nov 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8871907

    Glycosylated immunoglobulin and immunoadhesin comprising the same

    Expires Mon Oct 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8747845

    Methods of treatment by administering antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Expires Mon Jun 05 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8685931

    Hair growth methods using FGFR3 extracellular domains

    Expires Mon Mar 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8673375

    Herbal extract products and methods

    Expires Mon Mar 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Prime Medicine have?

127 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Prime Medicine patents expire?

1 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.